CMS throws drug companies under the spotlight

With help from Sarah Karlin and Brett Norman

CMS PUTS DRUGMAKER DATA UNDER THE SPOTLIGHT — The agency on Monday made public data on top-cost drugs in Medicare as well as brand and generic medicines that had the biggest price rises last year. The data make it easy for the public (and us!) to get a handle on some eye-popping stats on 80 drugs in Part B and Part D that represent $55 billion in spending out of more than $143 billion total. But CMS did not…

ORIGINAL SOURCE: Click Here to Continue Reading Article…